Physician profile
Moshe Rubin
NPI 1134217078
$2,071.38
in general payments reported to CMS, 2019-2025
15 companies · $94.03 in 2025
The $94.03 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $379 · 2021: $24.26 · 2024: $68.02 · 2025: $94.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.56 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.54 | 2019-2021 | |
| Fujifilm Healthcare Americas Corporation | $297.00 | 2019 | |
| Qol Medical, LLC | $200.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.37 | 2019-2025 | Entyvio |
| Olympus America INC. | $148.84 | 2019 | |
| Boston Scientific Corporation | $145.27 | 2019 | |
| Intercept Pharmaceuticals, INC. | $123.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $110.08 | 2019-2020 | |
| Janssen Biotech, INC. | $45.93 | 2019-2020 | |
| Pfizer INC. | $29.97 | 2024 | |
| Exact Sciences Corporation | $20.80 | 2025 | |
| Ironwood Pharmaceuticals, INC | $19.94 | 2024 | |
| Shire North American Group INC | $18.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.